Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -3M | -2M | -871K | 0 | 0 |
| Operating Income | -33M | -39M | -28M | -27M | -35M |
| EBITDA | -32M | -13M | -23M | -24M | -33M |
| Net Income | -36M | -18M | -26M | -28M | -36M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.52
-5.45% today
1Y Change
-93.72%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BiomX Inc. (PHGE) is a Healthcare stock with listed on AMEX. The stock last traded around $0.52 and down 93.7% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +20.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +20.6%, free cash flow +28.7% with operating margin 0.0% and ROIC -47.4%. Stock Foundry combines PHGE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHGE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHGE Max Drawdown
-96.97%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHGE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$36.2M
-27.9% YoY
Free Cash Flow
-$31.3M
-7.0% YoY
Revenue Growth
+0.0%
EPS Growth
+20.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -3M | -2M | -871K | 0 | 0 |
| Operating Income | -33M | -39M | -28M | -27M | -35M |
| EBITDA | -32M | -13M | -23M | -24M | -33M |
| Net Income | -36M | -18M | -26M | -28M | -36M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 18M | 15M | 31M | 62M |
| Total Assets | 70M | 43M | 25M | 46M | 78M |
| Total Liabilities | 72M | 19M | 22M | 24M | 30M |
| Shareholder Equity | -1M | 24M | 3M | 21M | 48M |
| Total Debt | 1M | 10M | 15M | 19M | 20M |
| Net Debt | -4M | -8M | 185K | -12M | -42M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
28M
+5.2% YoY
Capital Expenditures
4M
-3187.5% YoY
Free Cash Flow
31M
-7.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-274.0%
Debt / Equity
-1.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.